Virion Therapeutics, a privately held clinical-stage biotechnology company based in Philadelphia, announced on October 16, 2026, that long-term follow-up data for VRON-0200, its investigational T-cell-directed immunotherapy for chronic hepatitis B, have been selected for a late-breaking oral presentation at the American Association for the Study of Liver Diseases’ 2026 Liver Meeting. The conference will take place November 5 through November 9 in Denver, with the VRON-0200 presentation scheduled for November 9. The new analysis will focus on patients who received the experimental immunotherapy without additional investigational antiviral combinations.
The selected abstract describes durable or continuing declines in hepatitis B surface antigen lasting more than two years after a single dose of VRON-0200. However, Virion has not disclosed the complete numerical results from the forthcoming presentation in its October announcement. The findings build on a peer-reviewed Phase 1b study involving 35 participants, which previously demonstrated substantial immune activation and sustained antigen reductions in selected patients receiving stable nucleoside or nucleotide analogue treatment.
In the earlier analysis, 23 of 27 participants receiving VRON-0200 in the initial treatment groups, approximately 85%, had sustained or continuing hepatitis B surface antigen declines at Day 360. Longer follow-up was available for 12 participants, of whom 11 continued to demonstrate antigen reductions up to approximately 846 days after the original dose. These findings suggest that a single administration can produce prolonged biological effects, but they do not establish that hepatitis B infection has been eliminated.
Virion is developing VRON-0200 as a potential component of future treatment combinations intended to achieve a functional cure. This would require sustained loss of hepatitis B surface antigen and appropriate virological control after treatment cessation, rather than merely a reduction in antigen concentrations during continued antiviral therapy. The AASLD presentation will therefore be important for determining whether the emerging immune response is sufficiently durable to support more advanced clinical development.
Why is a functional cure difficult to achieve in chronic hepatitis B?
Chronic hepatitis B is a persistent viral infection that can cause progressive liver inflammation, fibrosis, cirrhosis and hepatocellular carcinoma. Although effective vaccines can prevent many new infections, hundreds of millions of people worldwide continue to live with chronic hepatitis B. The World Health Organization estimated approximately 254 million people had chronic infection in 2022, with more than one million deaths annually linked to associated complications.
Current treatment commonly involves nucleoside or nucleotide analogue medicines, including tenofovir and entecavir. These treatments can suppress viral replication effectively and reduce the risk of liver-related complications when used appropriately. However, most patients do not achieve sustained clearance of hepatitis B surface antigen, meaning treatment may need to continue for many years.
One reason is that hepatitis B can maintain persistent genetic material inside infected liver cells. This includes covalently closed circular DNA and, in some circumstances, integrated viral sequences capable of contributing to antigen production. Suppressing viral replication therefore does not necessarily eliminate the biological sources of persistent antigen.
Another challenge involves the immune response. Many people with chronic infection have weakened or dysfunctional HBV-specific T-cell activity, reducing the body’s ability to recognize and control infected cells. Restoring effective immunity is therefore considered an important potential component of future curative treatment strategies.
A functional cure generally refers to sustained hepatitis B surface antigen loss with appropriate control of viral replication after treatment. It is distinct from complete eradication of every viral genetic sequence. VRON-0200 is being investigated because it attempts to address the immune component of this challenge.
How does VRON-0200 attempt to restore hepatitis B-specific T-cell activity?
VRON-0200 is an investigational therapeutic immunotherapy delivered by intramuscular injection. It uses modified chimpanzee adenoviral vectors carrying genetic information associated with the hepatitis B core and polymerase proteins. The construct also incorporates Virion’s proprietary checkpoint modifier technology, intended to strengthen and prolong antiviral immune responses.
The decision to target core and polymerase rather than hepatitis B surface antigen is biologically significant. Virion aims to stimulate T cells against viral proteins involved in infection while monitoring changes in surface antigen as an indicator of antiviral activity. This approach differs from simply administering a vaccine designed to generate antibodies against the surface protein.
The company describes its technology as a way to enhance the breadth and persistence of T-cell responses that may be impaired during chronic infection. Its checkpoint modifier is intended to influence immune regulation locally in association with the vaccine response. Whether this can produce meaningful long-term viral control in patients remains under clinical investigation.
Because VRON-0200 is a therapeutic immunotherapy, it should not be confused with preventive hepatitis B vaccination. Preventive vaccines are administered to people who need protection against infection, whereas VRON-0200 is being investigated in patients who already have chronic hepatitis B. Its intended clinical outcome is therefore different from the establishment of protective antibody levels in previously uninfected individuals.
The programme also does not involve an approved treatment that can replace ongoing antiviral medication. Participants in the published Phase 1b investigation were receiving stable nucleoside or nucleotide analogue therapy, and the effect of stopping treatment has not been established by the reported data.
What did the published Phase 1b study demonstrate after one year?
The study, registered as NCT06070051, was a randomized, open-label, multicenter Phase 1b investigation involving adults with chronic hepatitis B. Participants were receiving stable antiviral therapy and had maintained undetectable circulating HBV DNA for at least 12 months. The study included patients with relatively low baseline surface antigen concentrations, a feature relevant to interpreting subsequent declines.
The peer-reviewed report, published in The Lancet Microbe in 2026, covered 35 enrolled participants. Of these, 27 entered groups evaluating VRON-0200 alone through single-dose or prime-and-boost regimens, while eight entered a separate investigation involving additional experimental antiviral agents. The primary endpoint concerned safety and tolerability, with immune and virological measurements assessed as additional outcomes.
At Day 360, 23 of the 27 participants in the initial groups demonstrated sustained or continuing reductions in hepatitis B surface antigen. Among those 23 patients, 12 experienced decreases exceeding 50% from baseline. Four of the 27 participants achieved reductions of at least one log10, corresponding to a decline of 90% or more.
These results suggest meaningful biological activity in a substantial proportion of the evaluated population. However, they do not establish that 85% of patients achieved a functional cure or that 85% experienced a large reduction in surface antigen. The 85% figure includes participants whose declines varied in magnitude.
The study also reported evidence of increased HBV-specific T-cell responses after treatment. At Day 28, interferon-gamma ELISpot responses increased approximately 3.2-fold from baseline, with a statistically significant result. Nevertheless, the investigators did not identify a clear association between the magnitude of this immune measurement and subsequent surface antigen declines.
That finding illustrates an important unresolved question. Demonstrating immune activation is valuable, but identifying which immune responses are responsible for durable viral control remains necessary for understanding the treatment mechanism.
What did the earlier two-year follow-up show about antigen suppression?
The published study included longer-term follow-up for 12 participants who had received VRON-0200. At the available observation point, extending to approximately 846 days after the initial dose, 11 of the 12 continued to demonstrate reductions in hepatitis B surface antigen. This provided early evidence that the biological effect might persist substantially beyond the original one-year assessment.
Among the 12 participants with extended follow-up, seven had surface antigen concentrations below 10 international units per milliliter. Four had concentrations below 0.5 IU/mL, and two had values below the assay’s lower limit of detection of 0.05 IU/mL. These measurements suggest that some patients reached very low antigen concentrations.
However, an assay result below its detection threshold is not automatically the same as confirmed, sustained functional cure. The clinical interpretation depends on repeated measurements, the treatment context and whether antigen loss persists after cessation of antiviral therapy. The published follow-up does not establish that all patients with very low antigen concentrations discontinued treatment successfully.
Another limitation involves patient selection. The longer-term analysis included 12 participants with available extended data, not all 27 originally treated in the main groups. Their outcomes may not represent the full study population.
The October 16 announcement indicates that the November presentation will provide complete long-term follow-up for participants receiving VRON-0200 alone. This may clarify the consistency and durability of the response across the broader relevant cohort. Until those figures are presented, the previously published results remain the appropriate numerical reference.
Why is the absence of antigen rebound important but not proof of cure?
Virion’s selected late-breaking abstract emphasizes durable or continuing hepatitis B surface antigen declines without rebound after a single VRON-0200 dose. A sustained reduction is potentially relevant because surface antigen production can persist despite effective antiviral suppression of HBV DNA. Reducing this antigen burden may support better restoration of antiviral immunity.
However, the term rebound requires careful interpretation. The announcement concerns surface antigen behavior during follow-up and does not establish that patients stopped their background nucleoside or nucleotide analogue therapy. Continued antigen decline while receiving antiviral treatment is different from sustained viral control after all treatment has ended.
Functional cure research frequently examines whether surface antigen becomes undetectable and remains so after a defined period without treatment. The clinical significance of a persistent decline is therefore greater when accompanied by an appropriate off-treatment assessment. The current announcement does not report that such an endpoint has been achieved.
The distinction also affects comparisons with other investigational hepatitis B medicines. Some agents directly reduce viral antigen production, while immunotherapies such as VRON-0200 aim to improve the patient’s immune response. The durability of a biomarker change may differ depending on the mechanism and the treatment combination.
Long-term observation is valuable because it can reveal whether an initial decline persists, deepens or reverses. Nevertheless, a complete functional cure claim requires evidence beyond a durable downward trend in surface antigen levels.
How did VRON-0200 perform when combined with additional antiviral agents?
The Phase 1b programme also evaluated VRON-0200 alongside elebsiran and tobevibart, two investigational antiviral agents. Elebsiran uses RNA interference to reduce hepatitis B-related transcripts, while tobevibart is an antibody designed to bind hepatitis B surface antigen. These mechanisms differ from VRON-0200’s intended T-cell-directed immune activity.
Seven participants in the combination group received the investigational antiviral regimen. The published study reported that all seven had surface antigen concentrations below 2 IU/mL within seven days of beginning the additional treatment. One participant had levels below the assay’s detection threshold at that early assessment.
At Day 196, approximately 28 days after the last investigational antiviral dose, all seven had surface antigen concentrations below 0.5 IU/mL. Three participants had levels below the lower limit of detection. At Day 259, approximately 91 days after the last antiviral dose, six of seven remained below 0.5 IU/mL and one remained below the detection threshold.
These results are encouraging but cannot establish that the combination achieved a functional cure. The participants continued background nucleoside or nucleotide analogue therapy, and the treatment group was very small. It is also difficult to isolate how much of the observed antigen reduction resulted from VRON-0200 rather than the direct antigen-lowering medicines.
The new AASLD presentation will focus on VRON-0200 alone, making its findings particularly relevant for understanding the duration of the immunotherapy’s biological effect without the confounding influence of the experimental combination. The distinction between these analyses should be maintained when evaluating the overall development programme.
What safety findings have been reported from the Phase 1b programme?
The published study reported 38 treatment-related adverse events among the 35 enrolled participants. Thirty-four were Grade 1 and four were Grade 2. No treatment-related serious adverse events, treatment discontinuations or clinically significant laboratory abnormalities were identified in the reported analysis.
The absence of notable liver function test abnormalities was particularly relevant because hepatitis B immunotherapies seek to activate immune responses in patients whose liver cells may contain persistent viral material. An excessively strong immune response could theoretically produce inflammation or liver injury. Investigators therefore need to assess antiviral immune activation alongside hepatic safety.
The available results support continued clinical development but cannot exclude uncommon complications. The study population was small and consisted largely of patients with controlled viral replication and normal liver function. Results may differ in patients with higher viral activity, advanced liver disease or other medical conditions.
The study also examined the response to different adenoviral vectors and dosing schedules. Investigators did not find evidence that adding a boost dose substantially improved surface antigen declines in the evaluated groups. This observation supports interest in a single-dose strategy but requires confirmation in larger studies.
Longer follow-up will provide information about delayed adverse events as well as antigen durability. The November presentation may help strengthen the safety assessment, although the announcement does not identify a new adverse reaction or a completed pivotal safety database.
What will the November 9 AASLD presentation establish?
Virion’s late-breaking oral presentation is scheduled for November 9, 2026, from 11:15 a.m. to 11:30 a.m. Mountain Time at The Liver Meeting in Denver. The presentation will be delivered by Professor Grace Lai-Hung Wong of The Chinese University of Hong Kong. The selected abstract is numbered 5016.
The company says the findings will cover complete long-term follow-up from the participants receiving VRON-0200 without the additional investigational antiviral combination. The detailed abstract is expected to become publicly available on November 5. As of October 17, those complete results have not yet been disclosed through the announcement.
The most useful information will concern how many participants continued to demonstrate surface antigen reductions, the magnitude of those changes and the duration of follow-up. Data on patients with very low or undetectable antigen levels may also be important. However, the interpretation must account for background antiviral treatment and the absence of a completed off-treatment functional cure assessment.
The presentation may also provide more information about immune responses and safety over the extended period. Such findings could support decisions about future dosing and combination strategies. They will not, by themselves, establish the efficacy of a registration-directed treatment programme.
What must Virion demonstrate before VRON-0200 can support a functional cure?
The central development challenge is to show that restoring HBV-specific immunity produces a benefit beyond short-term biomarker changes. A meaningful functional cure strategy must achieve sustained antigen loss and durable viral control under appropriately defined clinical conditions. Such outcomes are more demanding than observing antigen declines during antiviral suppression.
Larger studies will be needed to determine whether the Phase 1b findings are reproducible. Investigators must also evaluate patients with different baseline antigen levels and immune characteristics because the initial study selected participants with relatively low antigen concentrations. The treatment effect may not be identical across the broader chronic hepatitis B population.
Combination development represents another opportunity. Antigen-lowering medicines may reduce the viral protein burden while immunotherapy supports more effective T-cell responses. However, the sequence, duration and relative contribution of each component must be established through appropriately designed trials.
Virion’s long-term follow-up is scientifically interesting because it suggests that a single immune-directed treatment can be associated with sustained reductions in a marker that is difficult to eliminate through conventional antiviral therapy alone. The previously published findings provide measurable support for continued development, but they do not demonstrate cure.
The November AASLD presentation will help determine how durable and consistent the response has been across the evaluated monotherapy population. The ultimate clinical test will be whether VRON-0200 can become part of a treatment strategy that allows patients to maintain control of hepatitis B after antiviral treatment is discontinued.
